Drugs / Adrenocorticotrophic hormone
Adrenocorticotrophic hormone
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT01093157 Comparator | Feb 2010 → Jan 2013 | glomerulonephritis | University Health Network, Toronto | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-06-21 | Cerium Pharmaceuticals, Inc. | Cerium Pharmaceuticals receives FDA Orphan Drug Designation for Corticotropin (ACTH) porcine (synthetic) for the treatment of Membranous Nephropathy ceriumpharma.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adrenocorticotrophic hormone | “Drug: Adrenocorticotrophic hormone ACTH” NCT01093157 ↗ |
| Known as | ACTH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01093157 ↗ |
| Known as | corticotropin | “biologic ACTH, a slow-release formulation of corticotropin extracted from porcine pituitary glands (H.P. Acthar gel)” NCT01093157 ↗ |
| Modality | Protein / enzyme biologic | “biologic ACTH, a slow-release formulation of corticotropin extracted from porcine pituitary glands” NCT01093157 ↗ |
| Route | Subcutaneous | “of the ACTH gel subcutaneously” NCT01093157 ↗ |